Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS/MS.
A simple liquid chromatography/ion trap mass spectrometry method for the quantification of amlodipine and atorvastatin with its metabolites, ortho and para hydroxy atorvastatin, simultaneously in human plasma was developed. Analytes with internal standard were extracted by protein direct precipitation with acetonitrile. Adequate chromatographic separation was achieved using Phenomenex Synergi 4u polar-RP 80A (150mm×4.6mm, 4μm) column in the isocratic elution mode and the eluent was water/methanol (14:86%, v/v) adjusted by trichloroacetic acid to pH 3.2 which was delivered isocratically at constant flow rate of 0.50mL/min. Standard solutions for the analytes were prepared using amlodipine besylate, atorvastatin calcium, ortho-hydroxy atorvastatin dihydrate monosodium salt, para-hydroxy atorvastatin disodium salt, and pravastatin sodium as an internal standard. The method validation intends to investigate specificity, sensitivity, linearity, precision, accuracy, recovery, matrix effect and stability according to USFDA guideline. Standard calibration levels were prepared by pooled human plasma to attain final dynamic range of 0.2-20.0ng/mL for amlodipine, 1.5-150ng/mL for atorvastatin, 1.0-100.0ng/mL for ortho-hydroxy atorvastatin and 0.2-20.0ng/mL for para-hydroxy atorvastatin. Clinical bioequivalence study was successfully investigated by the application of this validated bioanalytical method in order to evaluate bioequivalence of two commercial products 10mg amlodipine/80mg atorvastatin in a single dose. In this study, 29 healthy volunteers were participated in randomized, two periods, double blend, open label cross over design. Pharmacokinetic parameters of C(max), AUC(0-t) and AUC(0-∞) were calculated to compare a test product with CADUET(®) reference product.
Jordan Center for Pharmaceutical Research, P.O. Box 950435, Amman 11105, Jordan. mahmood_yacoub@yahoo.com
Mahmoud
M
Yacoub
Ahmad Abu
AA
Awwad
Mahmoud
M
Alawi
Tawfiq
T
Arafat
D000284:Administration, Oral; D017311:Amlodipine / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D000069059:Atorvastatin; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D018592:Cross-Over Studies; D004338:Drug Combinations; D004355:Drug Stability; D006538:Heptanoic Acids / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D006801:Humans; D007536:Isomerism; D016014:Linear Models; D017035:Pravastatin / Q000097:blood; D011758:Pyrroles / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D053719:Tandem Mass Spectrometry / Q000379:methods*; D013810:Therapeutic Equivalency
D004338:Drug Combinations; D006538:Heptanoic Acids; D011758:Pyrroles; C487936:amlodipine, atorvastatin drug combination; D017311:Amlodipine; D000069059:Atorvastatin; D017035:Pravastatin